Update: 25.01.2021
Last week: 1 week 2022 (03.01.2022 - 09.01.2022)
Last full month: Dec 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | ||||||||
| WoW | 1 552 | -2.5% | 45.5% | 1.6 | 673 571 | -2.9% | 75.1% | 0.8 |
| MoM | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| YTD | 1 552 | -18.1% | 45.5% | -18.8 | 673 571 | 5.1% | 75.1% | -9.2 |
| MAT | 117 264 | -24.9% | 55.4% | -6.7 | 45 643 189 | -1.2% | 80.2% | -1.1 |
| CAPSICAM | ||||||||
| WoW | 18 013 | -20.2% | 3.6% | -0.6 | 7 411 490 | -20.0% | 3.9% | -0.7 |
| MoM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| YTD | 18 013 | -4.4% | 3.6% | 0.1 | 7 411 490 | -7.2% | 3.9% | -0.3 |
| MAT | 1 064 278 | -19.6% | 3.2% | -0.2 | 438 380 046 | -7.1% | 3.5% | -0.2 |
| MILDRONATE | ||||||||
| WoW | 71 930 | -4.8% | 11.6% | -0.1 | 28 224 726 | -4.3% | 17.1% | 0.6 |
| MoM | 417 135 | -7.8% | 12.3% | -0.2 | 162 253 267 | -6.5% | 17.5% | 0.1 |
| YTD | 71 930 | 9.1% | 9.0% | 0.3 | 28 224 726 | -1.8% | 13.5% | -0.6 |
| MAT | 4 801 693 | 11.8% | 9.3% | 1.4 | 1 933 027 911 | 16.4% | 14.1% | 2.2 |
| SULFARGIN | ||||||||
| WoW | 2 287 | -41.3% | 0.8% | -0.5 | 1 141 842 | -39.5% | 1.2% | -0.6 |
| MoM | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| YTD | 2 287 | -8.4% | 0.8% | 0 | 1 141 842 | -0.5% | 1.2% | 0.1 |
| MAT | 163 944 | -21.7% | 0.8% | -0.1 | 79 753 837 | -8.7% | 1.2% | -0.1 |
| VIPROSAL | ||||||||
| WoW | 22 832 | -16.4% | 4.5% | -0.6 | 9 003 076 | -18.1% | 4.7% | -0.7 |
| MoM | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| YTD | 22 832 | 27.0% | 4.5% | 1.2 | 9 003 076 | 27.2% | 4.7% | 1 |
| MAT | 1 248 380 | -12.2% | 3.7% | 0.1 | 473 203 531 | -2.8% | 3.8% | 0 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 1 552 | -2.5% | 45.5% | 1.6 | 673 571 | -2.9% | 75.1% | 0.8 |
| CAPSICAM | 18 013 | -20.2% | 3.6% | -0.6 | 7 411 490 | -20.0% | 3.9% | -0.7 |
| MILDRONATE | 71 930 | -4.8% | 11.6% | -0.1 | 28 224 726 | -4.3% | 17.1% | 0.6 |
| SULFARGIN | 2 287 | -41.3% | 0.8% | -0.5 | 1 141 842 | -39.5% | 1.2% | -0.6 |
| VIPROSAL | 22 832 | -16.4% | 4.5% | -0.6 | 9 003 076 | -18.1% | 4.7% | -0.7 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| CAPSICAM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| MILDRONATE | 417 135 | -7.8% | 12.3% | -0.2 | 162 253 267 | -6.5% | 17.5% | 0.1 |
| SULFARGIN | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| VIPROSAL | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 1 552 | -18.1% | 45.5% | -18.8 | 673 571 | 5.1% | 75.1% | -9.2 |
| CAPSICAM | 18 013 | -4.4% | 3.6% | 0.1 | 7 411 490 | -7.2% | 3.9% | -0.3 |
| MILDRONATE | 71 930 | 9.1% | 9.0% | 0.3 | 28 224 726 | -1.8% | 13.5% | -0.6 |
| SULFARGIN | 2 287 | -8.4% | 0.8% | 0 | 1 141 842 | -0.5% | 1.2% | 0.1 |
| VIPROSAL | 22 832 | 27.0% | 4.5% | 1.2 | 9 003 076 | 27.2% | 4.7% | 1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 117 264 | -24.9% | 55.4% | -6.7 | 45 643 189 | -1.2% | 80.2% | -1.1 |
| CAPSICAM | 1 064 278 | -19.6% | 3.2% | -0.2 | 438 380 046 | -7.1% | 3.5% | -0.2 |
| MILDRONATE | 4 801 693 | 11.8% | 9.3% | 1.4 | 1 933 027 911 | 16.4% | 14.1% | 2.2 |
| SULFARGIN | 163 944 | -21.7% | 0.8% | -0.1 | 79 753 837 | -8.7% | 1.2% | -0.1 |
| VIPROSAL | 1 248 380 | -12.2% | 3.7% | 0.1 | 473 203 531 | -2.8% | 3.8% | 0 |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs